Trial · NCT04350346
The Comparative Analysis Between Motilitone and Gasmotin for the Symptom Relief in Gallstone Patients With Functional Dyspepsia
NCT04350346, Not applicable, Unknown, Yonsei University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Comparative Analysis Between Motilitone and Gasmotin for the Symptom Relief in Gallstone Patients With Functional Dyspepsia. Trials, record NCT04350346. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04350346
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Comparative Analysis Between Motilitone and Gasmotin for the Symptom Relief in Gallstone Patients With Functional Dyspepsia
- NCT number
- NCT04350346
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Yonsei University
- Conditions
- Gallstone
- Interventions
- Motilitone, Gasmotin
- First posted
- 2020-04-17
- Last updated
- 2020-09-30
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Check symptom improvement | 3months (At the first outpatient visit 3months after administration) | The symptom score check should be completed at the first outpatient visit 3 months after administration. Nepean Dyspepsia Index- Korean version will be used to check the patient's indigestion symptoms. The questionnaire contains the following gastrointestinal symptoms How often it happened / how severe the symptoms were / how much it bothered you There are five (or six) answers. Gastrointestinal symptoms included Abdominal pain, Abdominal discomfort, Having a sour stomach, Heart burn, A Spasm of the stomach, Chest pain, Early fullness, Gastric acid reflux, Satiety after eating, pressure in the upper abdomen, Bloating of the upper abdomen, Nausea, Vomiting, Burp, Hard to breathe. The answer can be selected in 5 (6) numbers; from 0 to 4 (5). We will check the total score with the sum of each score. The symptom score is compared before and 3 months after administration. |
| Primary | Changes in serum concentrations of WBC count (10^3/µL), before and after the administration | 3months (At the first outpatient visit 3months after administration) | |
| Primary | Changes in serum concentrations of RBC count (10^6/µL), before and after the administration | 3months (At the first outpatient visit 3months after administration) | |
| Primary | Changes in serum concentrations of Hemoglobin (g/dL), before and after the administration | 3months (At the first outpatient visit 3months after administration) | |
| Primary | Changes in serum concentrations of BUN (mg/dL), before and after the administration | 3months (At the first outpatient visit 3months after administration) | |
| Primary | Changes in serum concentrations of Glucose (mg/dL), before and after the administration | 3months (At the first outpatient visit 3months after administration) | |
| Primary | Changes in serum concentrations of Albumin (g/dL), before and after the administration | 3months (At the first outpatient visit 3months after administration) | |
| Primary | Changes in serum concentrations of Total bilirubin (mg/dL), before and after the administration | 3months (At the first outpatient visit 3months after administration) | |
| Primary | Changes in serum concentrations of Direct bilirubin (mg/dL), before and after the administration | 3months (At the first outpatient visit 3months after administration) | |
| Primary | Changes in serum concentrations of Amylase (U/L), before and after the administration | 3months (At the first outpatient visit 3months after administration) |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04350346
GET https://conductscience.org/api/trials/v1/NCT04350346/registered?page=2